CREATION.co

Product Launch Tracker: HCPs welcomed the FDA’s approval of updated COVID-19 vaccines

11.09.2024 | Tracker

Product Launch Tracker: HCPs welcomed the FDA’s approval of updated COVID-19 vaccines

During August 2024, CREATION.co tracked the global conversations of 1,955 healthcare professionals (HCPs) who posted 3,337 times about the launches and approvals of new products.

On 02 August, the FDA approved the first gene therapy, Tecelra (afamitresgene autoleucel), to treat adults with metastatic synovial sarcoma. 73 HCPs shared their excitement towards the approval of the SPEAR T-Cell Receptor therapy including Clinical Oncology Pharmacist, Bichoy Gabra, as he shared more information on how TCR therapies work.

On 09 August the FDA approved epinephrine nasal spray for anaphylactic reaction and 181 HCPs shared 209 times regarding the approval on X. Dentist, Rajeev Chitguppi shared the approval saying that it was a ‘groundbreaking innovation’.

On 22 August, the FDA approved updated mRNA COVID-19 vaccines manufactured by Moderna and Pfizer. This was soon followed by the FDA approval of Novavax’s updated COVID-19 vaccine on 30 August. 375 HCPs shared about these approvals in 616 posts. Anesthesiologist, Jerome Adams, welcomed the approvals and stated that it is ‘great that people have a choice between mRNA and Novavax.’

The three most shared stories from HCPs discussing product launches in August were:

  • An FDA press release on approval of Novavax COVID-19 updated vaccine to better protect against currently circulating variants.
  • An FDA press release announcing the approval of the first nasal spray for treatment of anaphylaxis.
  • An FDA press release announcing the approval of neoadjuvant/adjuvant durvalumab for resectable non-small cell lung cancer.

Each month, CREATION.co tracks the HCP conversation relating to new product launches.

You can keep up to date with this and a variety of other topics including virtual congress, healthcare changes since the pandemic, product development and therapy area-specific insights within the Tracking section of CREATION Knowledge, or sign up to receive our monthly eJournal with all of our latest HCP insights. 

To stay up to date, you can sign up to CREATION.co’s monthly eJournal.

Methodology

  • CREATION Pinpoint® listened to the discussions amongst online HCPs of pharmaceutical product launches and drug approvals between 1 August and 31 August 2024.  
  • The data included mentions of drug approvals by the FDA, EMA, MHRA, NICE, and CHMP, as well as HCPs’ use of the phrase ‘drug approval’ in their posts.
  • Between 1 and 31 August 2024, 1,955 online HCPs worldwide made 3,337 references to new pharmaceutical product launches and drug approvals. 

 

 

 

Share this article

Meet the Author

Jessica Fernandes

After attaining a 1st class degree in Theology from Durham University, Jessica returned to Kent to join the graduate programme here at CREATION.co. She uses her research and analytical skills to inform health strategy and serve clients.

Outside of work, Jessica loves to travel and visit historical landmarks. She also enjoys mini-golf and going out for brunch with friends and family.

Suggested next

21.02.2024 | Case Study

Building a DOL Partnership to Differentiate in a Competitive Market

Differentiating their product in a competitive market by partnering with DOLs in oncology
CAR-T cell therapy: what we learned from 4,000 healthcare professionals

26.07.2018 | Article

CAR-T cell therapy: what we learned from 4,000 healthcare professionals

CAR-T cell therapy: what we learned from 4,000 healthcare professionals

By Daniel Ghinn

View all articles >